A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01539395

Enrollment

Registered

2012-02-27

Start date

2012-01-31

Completion date

2012-07-31

Last updated

2020-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Relapsing Remitting, MS

Brief summary

This is a Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis.

Interventions

OTHERMSDx Complex-1 Biomarker Test

A biomarker test for the level of MSDx Complex-1

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age 45 years or older of either gender and of any racial/ethnic group. 2. Subjects must be in generally good health. 3. Subjects must be able and willing to comply with the requirements of the protocol. 4. Must be diagnosed with RRMS 5. Meets the criteria to enter Group 1 or Group 2

Exclusion criteria

1. Subject is currently in middle of an active episode of an autoimmune condition (e.g. rheumatoid arthritis, system lupus erythematosis) 2. Subject currently has a condition such as active influenza that would stimulate the immune system

Design outcomes

Primary

Measure	Time frame	Description
Biomarker Differential	Baseline	A difference in the levels of Complex-1 between subjects with controlled, stable MS vs. subjects in acute MS relapse

Secondary

Measure	Time frame	Description
Biomarker reduction with steroid therapy	3 months	A decrease in the level of MSDx Complex-1 in response to steroid therapy for a relapse of MS.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026